Karl S. Dahlquist, AtriCure Inc.'s general counsel, sold 9,370 ordinary shares on August 24, 2026, for a total of $458,099 at prices between $48.88 and $48.89 per share. The transaction occurred as the company's stock approached its 52-week high of $49.88, following a 54% advance over the prior six months.
AtriCure's shares were down 1.05% in recent trading, while the company reported adjusted earnings of $0.18 per share for the second quarter of 2026, exceeding analyst expectations of a $0.01 loss. Revenue reached $153.6 million, surpassing the forecast of $151.84 million.
BTG raised AtriCure's price target from $45 to $55, maintaining a buy rating. The upgrade cited a new quality metric from the Society of Thoracic Surgeons that could bolster demand for AtriCure's Open Ablation products. Dahlquist retains a direct holding of 87,319 ordinary shares post-transaction. InvestingPro analysis indicated AtriCure was trading at a P/E ratio of 229, suggesting overvaluation relative to its fair value.
